ライフサイエンスコーパス: tenofovir alafenamide

1 received dolutegravir plus emtricitabine and tenofovir alafenamide).

2 enamide, 325 to dolutegravir, emtricitabine, tenofovir alafenamide).

3 cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide.

4 ignificantly reduced in patients given E/C/F/tenofovir alafenamide.

5 not suitable for NtRTIs such as abacavir or tenofovir alafenamide.

6 .48, 1.31-1.68) or without (1.25, 1.13-1.39) tenofovir alafenamide.

7 -label extension study of emtricitabine plus tenofovir alafenamide.

8 vir disoproxil fumarate and/or emtricitabine/tenofovir alafenamide.

9 ative hepatitis C virus serology, and use of tenofovir alafenamide.

10 compared tenofovir disoproxil fumarate with tenofovir alafenamide.

11 with those who remained on emtricitabine and tenofovir alafenamide.

12 ared with those receiving neither INSTIs nor tenofovir alafenamide.

13 %) continued bictegravir, emtricitabine, and tenofovir alafenamide.

14 ate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

15 ce of the antiretroviral drugs lopinavir and tenofovir alafenamide.

16 nistered with coformulated emtricitabine and tenofovir alafenamide.

17 n serum creatinine was small in both groups (tenofovir alafenamide 0.01 mg/dL [95% CI 0.00 to 0.02] v

18 ticipants who had received emtricitabine and tenofovir alafenamide (0.16 infections per 100 person-ye

19 to -0.15%), 7 for bictegravir/emtricitabine/tenofovir alafenamide (0.38% of participants vs 0.49% of

20 17-1.38), raltegravir (1.37, 1.20-1.56), and tenofovir alafenamide (1.38, 1.22-1.35) was significantl

21 1.70, 95% CI 1.54-1.88) or an INSTI without tenofovir alafenamide (1.41, 1.30-1.53) compared with th

22 d 1.74% to first-line NRTIs (0.89% tenofovir/tenofovir alafenamide, 1.74% abacavir, 1.07% lamivudine/

23 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg (tenofovir alafenamide group

24 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once per day.

25 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, which was taken once per da

26 cistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg) daily or continued therapy

27 egravir (30 mg), emtricitabine (120 mg), and tenofovir alafenamide (15 mg) for treatment of HIV in ch

28 Seven patients in the tenofovir alafenamide (2%) and three (1%) in the tenofov

29 ed (1:1) to receive either emtricitabine and tenofovir alafenamide (200/25 mg) tablets daily, with ma

30 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (the bictegravir group) or c

31 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (the bictegravir group) or d

32 with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg (the dolutegravir group), ea

33 ed to once-daily oral fixed-dose combination tenofovir alafenamide 25 mg and emtricitabine 200 mg, an

34 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or coformulated dolutegravir

35 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or dolutegravir 50 mg with c

36 status, to receive once-daily oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fuma

37 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, or coformulated dolutegravi

38 g with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg, with matching placebo, once

39 n with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg.

40 egravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) and no history of previous

41 ) with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks followed by s

42 ivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to continue a single-ta

43 ivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to remain on a single-t

44 to receive either emtricitabine (200 mg) and tenofovir alafenamide (25 mg) tablets daily, with matche

45 50 mg daily) with emtricitabine (200 mg) and tenofovir alafenamide (25 mg).

46 egravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg).

47 taneous lenacapavir (927 mg) plus oral daily tenofovir alafenamide (25 mg, group 1) or bictegravir (7

48 dy 2 (327 to bictegravir, emtricitabine, and tenofovir alafenamide, 325 to dolutegravir, emtricitabin

49 common adverse events overall were headache (tenofovir alafenamide 40 [14%] patients vs tenofovir dis

50 Tenofovir alafenamide, a tenofovir prodrug, results in 9

51 r with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, abacavir/dolutegravir/lamivudine,

52 coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virological suppression i

53 al and bone toxic effects; the novel prodrug tenofovir alafenamide achieves 90% lower plasma tenofovi

54 7-1.37), whereas the risk in those receiving tenofovir alafenamide alone became non-significant (1.15

55 22 (4%) patients receiving tenofovir alafenamide and 12 (4%) patients receiving ten

56 ents were randomly assigned (285 assigned to tenofovir alafenamide and 141 assigned to tenofovir diso

57 ) and AST (20 [3%] of 577 patients receiving tenofovir alafenamide and 19 [7%] of 288 patients receiv

58 person-year (95% CI 5.8-18.0) in women with tenofovir alafenamide and 2.9 per person-year (1.1-4.7)

59 ssigned and 873 received treatment (581 with tenofovir alafenamide and 292 with tenofovir disoproxil

60 At week 48, 296 (94%) of 316 participants on tenofovir alafenamide and 294 (94%) of 313 on tenofovir

61 received bictegravir plus emtricitabine and tenofovir alafenamide and 33 received dolutegravir plus

62 s in ALT (62 [11%] of 577 patients receiving tenofovir alafenamide and 36 [13%] of 288 patients recei

63 ed (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with efavirenz, emtricitab

64 treatment to 1733 patients (866 given E/C/F/tenofovir alafenamide and 867 given E/C/F/tenofovir diso

65 RETATION: Bictegravir plus emtricitabine and tenofovir alafenamide and dolutegravir plus emtricitabin

66 ants assigned to received emtricitabine plus tenofovir alafenamide and in those who switched from emt

67 ide-based regimens, and 38.4% (34.6-42.1) on tenofovir alafenamide and INSTI-based regimens had gaine

68 l development include novel oral agents (eg, tenofovir alafenamide and islatravir [also known as MK-8

69 nfected with RT-SHIV with oral emtricitabine/tenofovir alafenamide and long-acting cabotegravir/rilpi

70 14 (5%) patients receiving tenofovir alafenamide and nine (6%) patients receiving t

71 dy 1 (314 to bictegravir, emtricitabine, and tenofovir alafenamide, and 315 to dolutegravir, abacavir

72 fovir disoproxil fumarate than emtricitabine/tenofovir alafenamide, and QHPs were also more likely to

73 between weight gain and use of dolutegravir, tenofovir alafenamide, and raltegravir, particularly giv

74 egravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is rec

75 with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose combination to dol

76 tegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination versus

77 et darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as a potential switch option for t

78 t the use of bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and dur

79 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and dur

80 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and dur

81 Long-term use of emtricitabine and tenofovir alafenamide as daily oral PrEP is safe and wel

82 ble effects on total cholesterol compared to tenofovir alafenamide at the 12th and 24th months (p = 0

83 egravir plus co-formulated emtricitabine and tenofovir alafenamide at week 96.

84 long-term noninferior efficacy vs continuing tenofovir alafenamide-based regimens in treatment-experi

85 n NNRTI-based regimens, 37.4% (33.9-40.9) on tenofovir alafenamide-based regimens, and 38.4% (34.6-42

86 ese findings support guidelines recommending tenofovir alafenamide-based regimens, including coformul

87 1) to DTG + 3TC or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

88 mide and dolutegravir plus emtricitabine and tenofovir alafenamide both showed high efficacy up to 24

89 erability of bictegravir, emtricitabine, and tenofovir alafenamide compared with co-formulated dolute

90 erability of bictegravir, emtricitabine, and tenofovir alafenamide compared with dolutegravir plus co

91 ndomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and te

92 n containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivi

93 on-inferiority with a 10% efficacy margin of tenofovir alafenamide compared with tenofovir disoproxil

94 contrast, tenofovir disoproxil fumarate and tenofovir alafenamide conferred potentially cardioprotec

95 ether weight gain associated with INSTIs and tenofovir alafenamide confers a higher risk of weight-re

96 Switching to a tenofovir alafenamide-containing regimen from one contai

97 us RNA suppression while receiving a TDF- or tenofovir alafenamide-containing regimen.

98 Tenofovir alafenamide-containing regimens can have impro

99 rev, showed no impact on response to TDF- or tenofovir alafenamide-containing regimens.

100 Emtricitabine and tenofovir alafenamide continued to show superiority over

101 udy using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a

102 udy using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a

103 The novel prodrug tenofovir alafenamide delivers the nucleotide reverse tr

104 assigned to bictegravir, emtricitabine, and tenofovir alafenamide did not receive treatment).

105 nt taking bictegravir plus emtricitabine and tenofovir alafenamide discontinued because of a drug-rel

106 coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not require HLA B*5701 testin

107 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir group]).

108 h a more favorable lipid profile compared to tenofovir alafenamide during the first two years of trea

109 cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 3

110 eek 96, 276 (79%) of 351 participants in the tenofovir alafenamide, emtricitabine, and dolutegravir g

111 gain was substantial (7.1 kg [SD 7.4] in the tenofovir alafenamide, emtricitabine, and dolutegravir g

112 1 participants were randomly assigned to the tenofovir alafenamide, emtricitabine, and dolutegravir g

113 Participants in the tenofovir alafenamide, emtricitabine, and dolutegravir g

114 he clinically approved antivirals, including tenofovir alafenamide, emtricitabine, sofosbuvir, ledipa

115 Tenofovir alafenamide-emtricitabine (F/TAF) was recently

116 ernative regimens (lenacapavir + bictegravir/tenofovir alafenamide/emtricitabine and CAB + lenacapavi

117 g three combination antiretroviral regimens (tenofovir alafenamide/emtricitabine plus dolutegravir; d

118 nhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naiv

119 nt (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravi

120 ombination of 200 mg emtricitabine and 25 mg tenofovir alafenamide for 48 weeks.

121 Among participants taking emtricitabine plus tenofovir alafenamide for up to 144 weeks, markers of gl

122 Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and

123 generic F/TDF (gF/TDF), or emtricitabine and tenofovir alafenamide fumarate (F/TAF), or intramuscular

124 a dual-compartment topical insert containing tenofovir alafenamide fumarate (TAF) and elvitegravir (E

125 Tenofovir alafenamide fumarate (TAF) co-formulated with

126 Tenofovir alafenamide fumarate (TAF) co-formulated with

127 Tenofovir alafenamide fumarate (TAF), a new prodrug of t

128 disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide fumarate (TAF), is a key strategy

129 failure to receive second-line therapy with tenofovir alafenamide fumarate (TAF)-emtricitabine or st

130 egrase strand transfer inhibitor (-INSTI) or tenofovir alafenamide fumarate (TAF)-exposed persons, re

131 s (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF).

132 than in the dolutegravir, emtricitabine, and tenofovir alafenamide fumarate group (two [1%] of 208; p

133 217 to the dolutegravir, emtricitabine, and tenofovir alafenamide fumarate group, 215 to the doluteg

134 pregnancy: dolutegravir, emtricitabine, and tenofovir alafenamide fumarate; dolutegravir, emtricitab

135 seven participants in the emtricitabine and tenofovir alafenamide group (0.16 infections per 100 per

136 lated adverse events were more common in the tenofovir alafenamide group (204 patients [21%] vs 76 [1

137 325 in the dolutegravir, emtricitabine, and tenofovir alafenamide group (difference -1.9%, -7.8 to 3

138 omen to the dolutegravir, emtricitabine, and tenofovir alafenamide group (n=217), the dolutegravir, e

139 325 in the dolutegravir, emtricitabine, and tenofovir alafenamide group (study 2).

140 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and -0.10% (3.39) in the ten

141 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and -0.73% (3.21) in the ten

142 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group and 111 (91%) of 122 partici

143 er mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and 265 (84%) of 315 in the

144 er mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and 273 (84%) of 325 in the

145 630 participants were randomised (316 to the tenofovir alafenamide group and 314 to the tenofovir dis

146 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group and 34 (28%) of 122 particip

147 959 patients were randomly assigned to the tenofovir alafenamide group and 477 to the tenofovir dis

148 arate, with 800 (92%) of 866 patients in the tenofovir alafenamide group and 784 (90%) of 867 patient

149 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0% of patients (n=293

150 187 (32%) of 581 patients in the tenofovir alafenamide group and 96 (33%) of 292 patients

151 noted in 932 (97%) patients assigned to the tenofovir alafenamide group and in 444 (93%) assigned to

152 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and one (2%) participant in

153 s maintained in 314 (94%) of patients in the tenofovir alafenamide group compared with 307 (93%) in t

154 had study-drug related adverse events in the tenofovir alafenamide group compared with 37 (12%) of 31

155 ch significantly improved in patients in the tenofovir alafenamide group compared with those in the t

156 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group did not receive treatment an

157 pants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienced treatment-relate

158 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group had greater than or equal to

159 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group reported a serious adverse e

160 ts in the bictegravir plus emtricitabine and tenofovir alafenamide group versus 22 (67%) of 33 in the

161 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group versus 53 (43%) of 122 parti

162 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group versus five (2%) of 315 in t

163 f 2694 participants in the emtricitabine and tenofovir alafenamide group vs 49 [2%] of 2693 participa

164 ine 200 mg, and tenofovir alafenamide 10 mg (tenofovir alafenamide group) or to carry on taking one o

165 h matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine (200 mg)

166 h matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine and tenof

167 3 in the dolutegravir plus emtricitabine and tenofovir alafenamide group.

168 1.9%) in the bictegravir, emtricitabine, and tenofovir alafenamide group.

169 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group; 101 (31.4%) compared with 9

170 the receive bictegravir, emtricitabine, and tenofovir alafenamide group; 122 in the dolutegravir, em

171 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group; and bronchitis (six [11%]),

172 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group; and one (2%) in the tenofov

173 Patients given tenofovir alafenamide had a significantly smaller decrea

174 03 to 0.01]; p=0.32), but patients receiving tenofovir alafenamide had a smaller reduction in creatin

175 268 (94%) of 285 patients receiving tenofovir alafenamide had HBV DNA less than 29 IU/mL at

176 371 (64%) patients receiving tenofovir alafenamide had HBV DNA less than 29 IU/mL at

177 Emtricitabine and tenofovir alafenamide had more favourable effects on bon

178 Patients receiving tenofovir alafenamide had significantly smaller mean per

179 Patients given E/C/F/tenofovir alafenamide had significantly smaller mean ser

180 rmulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we

181 ty advantages, fixed-dose emtricitabine with tenofovir alafenamide has the potential to become an imp

182 rase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight g

183 ir disoproxil fumarate to emtricitabine with tenofovir alafenamide, high rates of virological suppres

184 icacy versus bictegravir, emtricitabine, and tenofovir alafenamide (HIV-1 RNA >=50 copies per mL, fiv

185 mol per million cells (IQR 1.7-13.3) for one tenofovir alafenamide implant and 14.8 fmol per million

186 initial 4-week safety assessment of a single tenofovir alafenamide implant in a small group of partic

187 -week assessment period of either one or two tenofovir alafenamide implants, with placebo implant com

188 .8 fmol per million cells (6.0-29.1) for two tenofovir alafenamide implants.

189 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-infected, treatment-naive a

190 ofovir disoproxil fumarate to one containing tenofovir alafenamide in participants aged 60 years and

191 of fixed-dose combination emtricitabine with tenofovir alafenamide in patients switched from emtricit

192 oxil fumarate switched to emtricitabine plus tenofovir alafenamide in the open-label phase, and 2070

193 2070 (77%) continued with emtricitabine plus tenofovir alafenamide in the open-label phase.

194 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people

195 ast quantifiable concentration (AUClast) for tenofovir alafenamide, incidence of treatment-emergent s

196 ommon in individuals receiving an INSTI with tenofovir alafenamide (IRR 1.70, 95% CI 1.54-1.88) or an

197 Tenofovir alafenamide is a novel prodrug formulated to d

198 Tenofovir alafenamide is a novel tenofovir prodrug that

199 Tenofovir alafenamide is a novel tenofovir prodrug with

200 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase strand

201 Tenofovir alafenamide is a prodrug that reduces tenofovi

202 Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was

203 Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is an effective therapy for adults

204 The prodrug tenofovir alafenamide is associated with improved renal

205 Tenofovir alafenamide is associated with less renal and

206 onsisting of bictegravir, emtricitabine, and tenofovir alafenamide is recommended for treatment of HI

207 Emtricitabine and tenofovir alafenamide is safe and effective for longer-t

208 Emtricitabine and tenofovir alafenamide maintained its non-inferiority to

209 all molecule that inhibits bitter taste from tenofovir alafenamide may increase the compliance in tre

210 tions with the backbone of emtricitabine and tenofovir alafenamide, might provide an advantage to pat

211 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (n=111 [66%]) or tenofovir disopro

212 ndomly assigned to receive emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and teno

213 omly assigned and received emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and teno

214 coformulated bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or coformulated dolutegrav

215 assigned to bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or dolutegravir, abacavir,

216 668 were randomly assigned to receive either tenofovir alafenamide (n=333) or tenofovir disoproxil fu

217 ction of NM1TFV, NM2TFV, or a nanoformulated tenofovir alafenamide (NTAF) at 75 mg/kg TFV equivalents

218 were assigned to receive emtricitabine plus tenofovir alafenamide, of whom 2693 and 2694, respective

219 domly assigned (2:1) to receive either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fum

220 weeks, more than 90% of patients given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fuma

221 ose 200 mg emtricitabine with 10 mg or 25 mg tenofovir alafenamide or to continue 200 mg emtricitabin

222 bine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fu

223 1) adults to bictegravir, emtricitabine, and tenofovir alafenamide, or dolutegravir 50 mg given with

224 f resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or tenofovir.

225 or continue bictegravir, emtricitabine, and tenofovir alafenamide orally once daily, with matching p

226 ndividually released approximately 0.1 mg of tenofovir alafenamide per day.

227 apply these methods to a completed trial of tenofovir alafenamide plus emtricitabine for PrEP.

228 94 (90%) of 438 participants assigned to the tenofovir alafenamide regimen and 402 (92%) of 437 assig

229 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was well tolerated and ach

230 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen were similar to those prev

231 Tenofovir alafenamide shows high antiviral efficacy and

232 Daily emtricitabine and tenofovir alafenamide shows non-inferior efficacy to dai

233 armacokinetics of an annual subdermal 110 mg tenofovir alafenamide silicone reservoir implant in HIV-

234 ted an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human im

235 potency of subcutaneous (SubQ) administrated tenofovir alafenamide (TAF) and emtricitabine (FTC) load

236 However, pooled analyses for tenofovir alafenamide (TAF) effects and comparisons betw

237 The TDF analogue tenofovir alafenamide (TAF) has demonstrated equal effic

238 and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have also proved effective i

239 ing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) improves renal tubular marke

240 udy assessed the penetration and efficacy of tenofovir alafenamide (TAF) in the male genital tract (M

241 Tenofovir alafenamide (TAF) is a novel prodrug of tenofo

242 In ART-naive people, tenofovir alafenamide (TAF) is frequently prescribed to

243 Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended tre

244 nfection, prompted us to evaluate TFV and/or Tenofovir alafenamide (TAF) release from FRT cells.

245 d nucleoside reverse transcriptase inhibitor tenofovir alafenamide (TAF) was decreased for some of th

246 lacing the alanyl isopropyl ester present in tenofovir alafenamide (TAF) with a docosyl phenyl alanyl

247 d from monomers that incorporate an ARV drug tenofovir alafenamide (TAF) with degradable linkers that

248 used vaginally in HIV prevention trials, and Tenofovir alafenamide (TAF), an improved prodrug of TFV,

249 aneous implants, especially those containing tenofovir alafenamide (TAF), can trigger local inflammat

250 that tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), drugs with excellent safety

251 ate dolutegravir (DTG) + emtricitabine (FTC)/tenofovir alafenamide (TAF), DTG + FTC/tenofovir disopro

252 weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the p

253 el (ENG)], or a formulation of a potent ARV [tenofovir alafenamide (TAF), or 4'-Ethynyl-2-fluoro-2'-d

254 once-daily fixed-dose DTG/3TC or remain on a tenofovir alafenamide (TAF)-based regimen.

255 Tenofovir alafenamide (TAF)-based regimens are being eva

256 from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF).

257 with HIV-1 and >=10% weight gain on INSTI + tenofovir alafenamide (TAF)/emtricitabine (FTC; <36 mont

258 soproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudi

259 tients given bictegravir, emtricitabine, and tenofovir alafenamide than in those given dolutegravir,

260 common with bictegravir, emtricitabine, and tenofovir alafenamide than with dolutegravir, abacavir,

261 ere initially assigned to emtricitabine plus tenofovir alafenamide, the incidence was 0.13 per 100 pe

262 feriority of bictegravir, emtricitabine, and tenofovir alafenamide to dolutegravir, abacavir, and lam

263 Non-inferiority of emtricitabine and tenofovir alafenamide to emtricitabine and tenofovir dis

264 CI -4.2 to 3.7), showing non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.

265 CI -2.5 to 5.1), showing non-inferiority of tenofovir alafenamide to tenofovir disproxil fumarate.

266 ty, while tenofovir disoproxil fumarate- and tenofovir alafenamide-treated cells and EMP displayed hi

267 contrast, tenofovir disoproxil fumarate and tenofovir alafenamide treatment gave rise to greater pop

268 GFR of 10 mL/min/1.73 m2 was observed in the tenofovir alafenamide treatment group (p < 0.001), while

269 last quantifiable concentration (AUClast) of tenofovir alafenamide, treatment-emergent serious advers

270 21 continued bictegravir, emtricitabine, and tenofovir alafenamide (two participants [one with a prot

271 ot predict progression to NAFLD or NASH, but tenofovir alafenamide use was associated with an increas

272 of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boo

273 re prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir

274 in patients switched to a regimen containing tenofovir alafenamide versus in those remaining on one c

275 f 320 in the bictegravir, emtricitabine, and tenofovir alafenamide versus six (2%) of 325 in the dolu

276 infection (51 [9%] of 581 patients receiving tenofovir alafenamide vs 22 [8%] of 292 patients receivi

277 iation [CV] 25.5%), and the mean AUClast for tenofovir alafenamide was 189 ng x h per mL (CV 55.8%).

278 t of variation 58%), and the mean AUClast of tenofovir alafenamide was 333 ng x h/mL (45%).

279 In October 2019, emtricitabine/tenofovir alafenamide was added as an approved formulati

280 In patients with HIV, tenofovir alafenamide was as efficacious as tenofovir di

281 d with incident hypertension, and the use of tenofovir alafenamide was associated with dyslipidaemia,

282 nucleotide reverse transcriptase inhibitors, tenofovir alafenamide was associated with more weight ga

283 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was efficacious and well tolerated

284 domly assigned to receive emtricitabine plus tenofovir alafenamide was estimated using a Poisson dist

285 coformulated bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to a dolutegravir

286 At week 144, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to both dolutegra

287 Switching to rilpivirine, emtricitabine, and tenofovir alafenamide was non-inferior to continuing ril

288 At week 96, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to dolutegravir,

289 E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovi

290 0% had completed 96 weeks) emtricitabine and tenofovir alafenamide was non-inferior to emtricitabine

291 patients with HBeAg-positive HBV infection, tenofovir alafenamide was non-inferior to tenofovir diso

292 HBeAg-negative chronic HBV, the efficacy of tenofovir alafenamide was non-inferior to that of tenofo

293 mbination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated compar

294 Bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated with b

295 Emtricitabine and tenofovir alafenamide was superior to emtricitabine and

296 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide were higher, but modestly so, than

297 Most metabolites associated with tenofovir alafenamide were not associated with tenofovir

298 e and fractures, our data suggest that E/C/F/tenofovir alafenamide will have a favourable long-term r

299 ttenuated the risk in participants receiving tenofovir alafenamide with an INSTI (adjusted IRR 1.21,

300 and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz